Published in J Pharmacol Exp Ther on August 25, 2008
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci (2008) 1.32
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov (2009) 1.22
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. Psychopharmacology (Berl) (2009) 1.19
Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues. Neuropsychopharmacology (2009) 1.19
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry (2011) 1.18
Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology (2013) 1.14
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 1.08
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One (2012) 1.05
Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci (2015) 1.04
The dark side of emotion: the addiction perspective. Eur J Pharmacol (2015) 1.03
Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings. Neuropsychopharmacology (2012) 1.01
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav (2011) 0.98
Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors. Addict Biol (2010) 0.97
The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. Br J Pharmacol (2011) 0.96
The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci (2011) 0.94
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology (2011) 0.94
Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence. Curr Drug Targets (2013) 0.94
Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse. Neuropsychopharmacology (2015) 0.93
The cannabinoid CB2 receptor is necessary for nicotine-conditioned place preference, but not other behavioral effects of nicotine in mice. Psychopharmacology (Berl) (2013) 0.93
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther (2013) 0.92
Hub and switches: endocannabinoid signalling in midbrain dopamine neurons. Philos Trans R Soc Lond B Biol Sci (2012) 0.89
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol (2012) 0.87
Role of cues and contexts on drug-seeking behaviour. Br J Pharmacol (2014) 0.87
The endocannabinoid system: a new molecular target for the treatment of tobacco addiction. CNS Neurol Disord Drug Targets (2008) 0.85
Animal models of cannabinoid reward. Br J Pharmacol (2010) 0.84
Endocannabinoids and the processing of value-related signals. Front Pharmacol (2012) 0.83
Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide. Psychopharmacology (Berl) (2010) 0.82
The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB₁- and FAAH-independent mechanisms. Br J Pharmacol (2013) 0.81
Drug addiction. Curr Top Behav Neurosci (2009) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking. J Psychopharmacol (2013) 0.81
The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area. Neuropsychopharmacology (2012) 0.81
Antireward, compulsivity, and addiction: seminal contributions of Dr. Athina Markou to motivational dysregulation in addiction. Psychopharmacology (Berl) (2017) 0.80
THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction. Transl Psychiatry (2013) 0.79
Chronic stimulation of the tone of endogenous anandamide reduces cue- and stress-induced relapse in rats. Int J Neuropsychopharmacol (2014) 0.79
Role of the endogenous cannabinoid system in nicotine addiction: novel insights. Front Psychiatry (2015) 0.79
Applying a multitarget rational drug design strategy: the first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase. Chem Commun (Camb) (2014) 0.77
Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats. Psychopharmacology (Berl) (2013) 0.77
Quantification of anandamide, oleoylethanolamide and palmitoylethanolamide in rodent brain tissue using high performance liquid chromatography-electrospray mass spectroscopy. J Pharm Anal (2014) 0.76
Attenuating Nicotine Reinforcement and Relapse by Enhancing Endogenous Brain Levels of Kynurenic Acid in Rats and Squirrel Monkeys. Neuropsychopharmacology (2017) 0.75
Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives. Psychopharmacology (Berl) (2016) 0.75
Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats. Br J Pharmacol (2013) 0.75
Dissociating the role of endocannabinoids in the pleasurable and motivational properties of social play behaviour in rats. Pharmacol Res (2016) 0.75
Nicotine self-administration research: the legacy of Steven R. Goldberg and implications for regulation, health policy, and research. Psychopharmacology (Berl) (2016) 0.75
Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice. Psychopharmacology (Berl) (2015) 0.75
Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats. Psychopharmacology (Berl) (2016) 0.75
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 6.27
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 5.22
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature (1996) 4.52
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature (2005) 4.15
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A (2005) 2.96
Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res (1994) 2.95
Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) (1989) 2.78
Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol (2002) 2.68
Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev (2006) 2.25
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci (2004) 1.85
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
The beta2 but not alpha7 subunit of the nicotinic acetylcholine receptor is required for nicotine-conditioned place preference in mice. Psychopharmacology (Berl) (2006) 1.76
Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol (2007) 1.75
SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol (2002) 1.75
Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem (2003) 1.59
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) (1997) 1.54
Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. Br J Pharmacol (2002) 1.53
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) (2004) 1.48
Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse (2003) 1.38
Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res (2002) 1.38
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 1.37
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) (2005) 1.35
Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol (2007) 1.32
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther (2006) 1.31
Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology (2002) 1.29
Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol (1987) 1.26
Reinstatement and spontaneous recovery of nicotine seeking in rats. Psychopharmacology (Berl) (1997) 1.17
Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) (2005) 1.12
The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav (2005) 1.09
Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci (2003) 1.08
The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther (2008) 1.07
Cannabinoids and memory: animal studies. Curr Drug Targets CNS Neurol Disord (2003) 1.07
The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology (2007) 1.00
The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors. Mol Pharmacol (2007) 1.00
The effects of anandamide on memory consolidation in mice involve both D1 and D2 dopamine receptors. Behav Pharmacol (1997) 0.88
Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes. J Neurochem (2008) 0.87
Use of knock-out mice to determine the molecular basis for the actions of nicotine. Nicotine Tob Res (1999) 0.87
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Role of endogenous cannabinoids in synaptic signaling. Physiol Rev (2003) 5.70
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature (2003) 4.60
An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 4.03
The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol (2004) 3.38
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther (2004) 3.14
Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry (2012) 2.87
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med (2009) 2.82
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci (2010) 2.73
A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci (2002) 2.52
Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci (2011) 2.31
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci (2006) 2.29
Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products. Neuropsychopharmacology (2012) 2.28
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol (2004) 2.12
Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) (2004) 2.07
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids (2002) 1.98
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther (2007) 1.96
Albuminuria and dementia in the elderly: a community study. Am J Kidney Dis (2008) 1.96
Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci (2005) 1.92
PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab (2010) 1.91
Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology (2012) 1.91
Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. J Affect Disord (2011) 1.91
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther (2004) 1.83
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol (2006) 1.83
Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron (2003) 1.80
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry (2007) 1.79
Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem (2004) 1.73
Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem (2006) 1.71
The search for the palmitoylethanolamide receptor. Life Sci (2005) 1.68
Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol (2005) 1.66
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms--a review of recent preclinical data. Psychopharmacology (Berl) (2003) 1.66
Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A (2009) 1.64
Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem (2004) 1.63
A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol Pharmacol (2007) 1.63
Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) (2003) 1.59
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 1.55
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther (2007) 1.53
Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain. Front Biosci (2008) 1.52
Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem (2003) 1.50
A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2011) 1.50
Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology (2005) 1.49
Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl) (2004) 1.48
Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors. J Pharmacol Exp Ther (2011) 1.47
Reinforcing effects of sigma-receptor agonists in rats trained to self-administer cocaine. J Pharmacol Exp Ther (2009) 1.45
Would you refer this patient to hospice? An evaluation of tools for determining life expectancy in end-stage dementia. J Palliat Med (2007) 1.44
The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology (2005) 1.43
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Sex differences in drug addiction: a review of animal and human studies. Womens Health (Lond Engl) (2008) 1.42
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology (2003) 1.41
Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry (2010) 1.39
Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl) (2002) 1.39
Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse (2003) 1.38
Granular insular cortex inactivation as a novel therapeutic strategy for nicotine addiction. Biol Psychiatry (2010) 1.38
Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport (2004) 1.37
Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett (2008) 1.36
Environmental enrichment reduces cocaine seeking and reinstatement induced by cues and stress but not by cocaine. Neuropsychopharmacology (2009) 1.35
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem (2006) 1.35
Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) (2005) 1.35
Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci (2008) 1.32
Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol (2009) 1.31
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther (2006) 1.31
Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc Natl Acad Sci U S A (2002) 1.30
Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide. Neuropsychopharmacology (2003) 1.30
The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings. Front Neuroendocrinol (2007) 1.30
Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum. J Biol Chem (2008) 1.30
Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci U S A (2011) 1.29
High reinforcing efficacy of nicotine in non-human primates. PLoS One (2007) 1.29
Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci (2011) 1.29
Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample. Am J Addict (2013) 1.29
Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology (2006) 1.28